| HOME >> BIOLOGY >> TECHNOLOGY |
---15.0Restructuring & other special items
15.431.846.062.3Tax effect of the above items
(53.2)(79.7)(130.2)(165.9)Preferred dividend (b)
-34.8-104.3Adjusted net earnings attributable to Mylan Inc. and adjusted diluted EPS
$237.8
$0.55$189.0
$0.43$666.5
$1.51$510.6
$1.16Weighted average diluted common shares outstanding (b)
431.6437.9441.8438.2(a) Purchase accounting related amortization expense for the three and nine months ended September 30, 2011 includes a $16.2 million in-process research and development asset impairment charge. (b) Adjusted diluted EPS for the three and nine months ended September 30, 2010, was calculated under the "if-converted method" which assumes conversion of the company's preferred stock into 125.2 million shares of common stock, based on an average share price, and excludes the preferred dividend from the calculation, as the "if-converted method" is more dilutive.Below is a reconciliation of GAAP net earnings attributable to Mylan Inc. to adjusted EBITDA for the three and nine months ended September 30, 2011, and 2010 (in millions): Three months ended September 30,Nine months ended September 30,2011201020112010GAAP net earnings attributable to Mylan Inc. before preferred dividends
$
56.7$
43.2$
407.3$
325.3Add/(Deduct):Net contribution attributable to the noncontrolling interest and equity method investees
0.70.41.6(0.6)Income taxes
34.8(12.0)116.933.3Interest expense
85.887.5254.8240.0Depreciation and amortization (a)
141.7108.0386.6312.9EBITDA
$
419.7$
327.1$ 1,167.2$
910.9Add Adjustments:Stock-based compensation expense
11.68.532.824.1Litigation settlements, net
2.21.528.514.3Restructuring & other special items
13.431.042.176.5Adjusted EBITDA
$
446.9$
368.1$ 1,270.6$ 1,025.8(a) Depreciation and amortization expense fo
'/>"/>
| SOURCE Mylan Inc. Copyright©2010 PR Newswire. All rights reserved |